CN114729945B - 通过与磷酸化tau蛋白结合检测神经疾病的方法 - Google Patents

通过与磷酸化tau蛋白结合检测神经疾病的方法

Info

Publication number
CN114729945B
CN114729945B CN202080079435.3A CN202080079435A CN114729945B CN 114729945 B CN114729945 B CN 114729945B CN 202080079435 A CN202080079435 A CN 202080079435A CN 114729945 B CN114729945 B CN 114729945B
Authority
CN
China
Prior art keywords
compound
disease
use according
alkyl
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080079435.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114729945A (zh
Inventor
S·萨拉夫
S·拉苏尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amidas
Original Assignee
Amidas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amidas filed Critical Amidas
Publication of CN114729945A publication Critical patent/CN114729945A/zh
Application granted granted Critical
Publication of CN114729945B publication Critical patent/CN114729945B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080079435.3A 2019-09-18 2020-09-17 通过与磷酸化tau蛋白结合检测神经疾病的方法 Active CN114729945B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902265P 2019-09-18 2019-09-18
US62/902,265 2019-09-18
PCT/US2020/051325 WO2021055639A1 (en) 2019-09-18 2020-09-17 Methods of detecting neurological disorders via binding to phosphorylated tau protein

Publications (2)

Publication Number Publication Date
CN114729945A CN114729945A (zh) 2022-07-08
CN114729945B true CN114729945B (zh) 2025-09-02

Family

ID=74883484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080079435.3A Active CN114729945B (zh) 2019-09-18 2020-09-17 通过与磷酸化tau蛋白结合检测神经疾病的方法

Country Status (7)

Country Link
US (1) US20220370642A1 (https=)
EP (1) EP4031879A4 (https=)
JP (2) JP7591040B2 (https=)
CN (1) CN114729945B (https=)
AU (1) AU2020348382A1 (https=)
CA (1) CA3154481A1 (https=)
WO (1) WO2021055639A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52796A (fr) 2018-05-31 2021-04-14 Amydis Inc Compositions et procédés de détection d'une lésion cérébrale traumatique
WO2022266210A1 (en) * 2021-06-16 2022-12-22 The Regents Of The University Of California Amyloid targeting agents and methods of using the same
JP2024525693A (ja) * 2021-07-15 2024-07-12 アミディス， インコーポレイテッド 神経変性障害の診断のためにアミロイドおよびアミロイド様タンパク質を検出するためのフルオロフォアとしてのｎ－ヘテロシクリル置換２－シアノ－３－（ナフタレン－２－イル）アクリルアミド誘導体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573880B (zh) * 2014-03-19 2019-07-30 阿米达斯公司 淀粉样蛋白靶向剂及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102115429B (zh) * 2010-01-06 2013-02-27 中国科学院上海药物研究所 (e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途
RU2627694C2 (ru) * 2010-10-29 2017-08-10 Клино Лтд. Производные хинолина, визуализирующий белок тау
WO2016040891A2 (en) * 2014-09-12 2016-03-17 Amydis Diagnostics In vitro compositions comprising human sample and amyloid targeting agent
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
MA52796A (fr) * 2018-05-31 2021-04-14 Amydis Inc Compositions et procédés de détection d'une lésion cérébrale traumatique
AU2019372432B2 (en) * 2018-11-02 2025-05-29 Amydis, Inc. Phosphate compounds for detecting neurological disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573880B (zh) * 2014-03-19 2019-07-30 阿米达斯公司 淀粉样蛋白靶向剂及其使用方法

Also Published As

Publication number Publication date
WO2021055639A1 (en) 2021-03-25
JP2024177285A (ja) 2024-12-19
AU2020348382A1 (en) 2022-04-28
JP7591040B2 (ja) 2024-11-27
US20220370642A1 (en) 2022-11-24
JP2022548158A (ja) 2022-11-16
EP4031879A4 (en) 2023-11-15
CA3154481A1 (en) 2021-03-25
EP4031879A1 (en) 2022-07-27
CN114729945A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
US11718596B2 (en) Amyloid targeting agents and methods of using the same
CN114729945B (zh) 通过与磷酸化tau蛋白结合检测神经疾病的方法
US12435047B2 (en) c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same
CN113271944B (zh) 用于对神经疾病进行检测的磷酸盐化合物
JP7583895B2 (ja) 外傷性脳損傷を検出するための組成物および方法
CN117916225A (zh) N-杂环基取代的2-氰基-3-(萘-2-基)丙烯酰胺衍生物作为荧光团用于检测类淀粉蛋白和类淀粉样蛋白以诊断神经退行性病症
CN120569365A (zh) 类淀粉蛋白靶向剂
CN121991127A (zh) 用于对神经疾病进行检测的磷酸盐化合物
HK40061967B (en) Phosphate compounds for detecting neurological disorders
HK40061967A (en) Phosphate compounds for detecting neurological disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant